Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT-101 + Atezolizumab in Metastatic NSCLC
NCT05935774Phase 2Withdrawn
- Sponsor
- University of Washington
- Start
- Dec 2023
- Primary completion
- Jul 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of trabedersen in non-small cell lung cancer (NSCLC), sponsored by University of Washington. Planned start Dec 2023; status: withdrawn.
02
Drugs
trabedersen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05935774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935774.